Infliximab in the treatment of crohn disease and type 1 diabetes

Diabetes Care

Volumn 36, Issue 7, 2013, Pages

  Timper, Katharina ^a   Hruz, Petr ^a   Beglinger, Christoph ^a   Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CALGRANULIN; GLUCOSE; HEMOGLOBIN A1C; INFLIXIMAB; INSULIN; INSULIN GLARGINE; INSULIN LISPRO;

ABDOMINAL DISCOMFORT; ADULT; CASE REPORT; CROHN DISEASE; DIARRHEA; FECES ANALYSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LETTER; MALE; REMISSION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIABETES MELLITUS, TYPE 1; HUMANS; MALE;

EID: 84886030917     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0199     Document Type: Letter

References (5)

1. Colombel JF, Sandborn WJ, Reinisch W, et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395
2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
3. Yang XD, Tisch R, Singer SM, et al. Effect of tumor necrosis factor alpha on insulindependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004
4. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with newonset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-1249
5. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107